[Feature Stock] Suzentec surges due to additional Hantavirus cases… WHO warns of incubation period, diagnostic kit stocks highlighted

SUZENTEK is showing strong performance intraday amid news that a collective Hantavirus infection outbreak is spreading. The World Health Organization (WHO) warns that the incubation period could last as long as 6 to 8 weeks, prompting buying interest in stocks related to infectious disease diagnosis.

In the market, SUZENTEK is up 24.46% from the previous trading day, trading at 7,530 Korean won. After a collective infection occurred on the cruise ship “MV Hondius,” countries including France, the United States, and Spain reported more confirmed cases, which is believed to have boosted investor sentiment.

According to foreign media and health authorities, the confirmed virus is an Andes-type Hantavirus that may be transmissible between people. The WHO counts the officially confirmed cases as 7 and says it is monitoring the situation in case more cases emerge. Health departments in various countries have also put in place hospital isolation and home isolation measures for returning passengers to strengthen monitoring systems.

During the COVID-19 pandemic, SUZENTEK previously built up global supply experience with rapid diagnostic test kits and immunodiagnostic platforms. Analysts believe that because the company has multiple infectious disease diagnostic platforms, the expectation of increased demand for in vitro diagnostics amid the spread of infectious disease is being reflected in the stock price.

Previously, SUZENTEK’s stock price had been showing sensitive fluctuations in response to infectious disease events. The market believes that as health agencies around the world increase their response levels, attention to diagnostic test kits and infectious-disease-related stocks may continue.